StockNow
Calendar
Log in
U.S. Markets

Edwards Lifesciences (EW) weighed following recent progress trial update on TAVR

ORIGINAL · NewsquawkEdwards Lifesciences (EW) weighed following recent progress trial update on TAVR
StockNow breaking-news AI analysis

The Edwards breaking-news record lacks supporting text. A separate Proactive report gives Anteris DurAVR’s 30-day EMBARK results and PARADIGM trial details, without establishing an EW impact.

1 stocks
EWEdwards Lifesciences Corp$92.02Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Anthropic (ANT) Q3 2026 (USD): Net Loss 23.3bln (prev. Loss 12.1bln Y/Y), Revenue 16.96bln (prev. 1.38bln Y/Y), Total Operating Expenses 17.5bln (prev. 4.47bln Y/Y)

Geopolitics

Iran threatens US bases in Europe if US President Trump orders new strikes, reports The Times

U.S. Markets

Alphabet (GOOGL) set to raise EUR 6bln from a euro bond sale, Bloomberg reports

GOOGLGOOG